

# The United States vs. Other Countries: Availability of Part B Medicines Varies

The Most Favored Nation rule would set U.S. prices for medicines covered under Medicare Part B based on the pricing policies of 22 foreign governments – many of which set prices artificially low, resulting in severe access restrictions for patients.

	New Part B Medicines Available	Average Delay in Availability of New Part B Medicines
 Iceland*	N/A	N/A
 Israel*	N/A	N/A
 Luxembourg*	N/A	N/A
 New Zealand	26%	25 months
 Korea	35%	25 months
 Australia	35%	19 months
 Canada	37%	16 months
 Ireland	42%	20 months
 Italy	46%	20 months
 Belgium	48%	24 months
 Japan	48%	26 months
 Spain	49%	22 months
 Switzerland	54%	17 months
 France	54%	17 months
 Finland	57%	14 months
 Norway	58%	14 months
 Denmark	58%	12 months
 Netherlands	60%	8 months
 Sweden	62%	8 months
 United Kingdom	62%	11 months
 Austria	63%	11 months
 Germany	66%	10 months
 <b>United States</b>	<b>100%</b>	<b>0-3 months</b>

Source: PhRMA analysis of IQVIA Analytics Link and U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) data. June 2020. Note: New active substances approved by FDA, EMA and/or PMDA and first launched in any country between January 1, 2011, and December 31, 2019. \*Data for Iceland, Israel and Luxembourg are currently unavailable.